Phase 3 study of oral vadadustat versus darbepoetin alfa for maintenance treatment of anemia in dialysis-dependent chronic kidney disease

Phase 3, randomised, open-label trial of vadadustat in anemia of renal disease (2 arms), sponsored by Akebia Therapeutics. Primary endpoints: Mean change in hemoglobin from baseline to the primary evaluation period and Major adverse cardiovascular events. Started Jan 2017; status: recruiting.